Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
<p><strong>Background</strong></p> <p>Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of...
Main Authors: | Mullen, M, Jin, X, Child, A, Hu, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2019
|
Similar Items
-
A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.
by: Mullen, M, et al.
Published: (2013) -
Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
by: Haynes, R, et al.
Published: (2018) -
Estimation of treatment allocation in a randomised, double-blinded, placebo-controlled trial
by: Milica Popovic, et al.
Published: (2019-07-01) -
Montelukast for postinfectious cough in adults: a double-blind randomised placebo-controlled trial.
by: Wang, K, et al.
Published: (2014) -
Montelukast for postinfectious cough in adults: a double-blind randomised placebo-controlled trial
by: Wang, K, et al.
Published: (2013)